Allos Therapeutics Inc is developing the hemoglobin allosteric modifier efaproxiral as a potential radiosensitizer and chemotherapy enhancer in cancer therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
allos therapeutics
8
efaproxiral allos
4
therapeutics allos
4
therapeutics developing
4
developing hemoglobin
4
hemoglobin allosteric
4
allosteric modifier
4
modifier efaproxiral
4
efaproxiral potential
4
potential radiosensitizer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!